Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect
New code is expected to advance commercialization efforts in doctors’ offices and other outpatient settingsFRAMINGHAM, Mass., April 05, 2023 (GLOBE...
Medicare
ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments
ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family...
Milestone Scientific Provides 2022 Year-End Business Update
ROSELAND, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
InvestmentPitch Media Video Discusses Reliq Health and its Signing of 10 Contracts Potentially Adding 5,000 new Patients to its iUGO Platform by Year End
VANCOUVER, British Columbia, March 31, 2023 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
MedAvail Postpones Reporting of Fourth Quarter and FY 2022 Financial Results
PHOENIX, March 30, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ: MDVL) (“MedAvail” or the “Company”), an innovative pharmacy technology...
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...
G MEDICAL INNOVATIONS AND ADVENTHEALTH IN JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS FOR ADVENTHEALTH PATIENTS IN CENTRAL FLORIDA
Rehovot, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical...
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied...
BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023...
Amedisys Supports New Research that Demonstrates the Value of Hospice Care Through Better Outcomes and Medicare Savings
BATON ROUGE, La., March 23, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice,...
Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
iCAD’s Breast AI Suite Empowers Customers to Lead the Way in Support of FDA’s National Breast Density Reporting Standard
iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual ConferenceNASHUA, N.H., March 23, 2023 (GLOBE...
BioStem Technologies Commends OIG’s Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products
POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies (“BioStem” or the “Company”) (OTCQB: BSEM), a leading provider...
Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area...
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Dupixent®(dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More...
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks...
MIMEDX Comments on Recent Data Brief Published by Office of Inspector General
Company applauds the Office of Inspector General’s (“OIG”) recommendation for the Centers for Medicare and Medicaid Services (“CMS”) to quickly...
Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2022 Financial Results
Revenue increased 9.0% to $451.1 million, compared to Q4 2021 Gross margin increased 3.5% to $128.8 million, compared to Q4...
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
Company is exploring strategic options for its Therapy business lineNASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD),...